NCT07106528View on ClinicalTrials.gov

Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Extensive-stage Small Cell Lung Cancer (SCLC)Small Cell Lung Cancer ( SCLC )
Interventions
DRUG

Organoid Drug Sensitivity Testing-Guided Therapy

Personalized drug selection (chemotherapy/targeted therapy/immunotherapy) based on ex vivo organoid drug response testing

DRUG

Topotecan

Intravenous topotecan 1.25 mg/m² daily on days 1-5 of each 21-day cycle

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER